Published in J Clin Microbiol on February 01, 1988
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71
Effect of urease on HeLa cell vacuolation induced by Helicobacter pylori cytotoxin. Infect Immun (1991) 3.57
Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 3.49
Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol (1992) 2.95
Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol (1997) 2.90
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol (2002) 2.89
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol (2007) 1.87
Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1988) 1.86
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods (2013) 1.66
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A (1989) 1.64
Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 1.63
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol (1999) 1.62
Quantitative colorimetric microneutralization assay for characterization of adenoviruses. J Clin Microbiol (1994) 1.60
Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A (2000) 1.57
Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol (1999) 1.55
Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol (2003) 1.53
Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology (2009) 1.51
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol (1998) 1.43
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol (2001) 1.42
Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol (2002) 1.40
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol (1998) 1.39
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol (1999) 1.37
CD4+-T-cell and CD20+-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection in macaques. J Virol (1998) 1.36
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A (1992) 1.35
Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol (2011) 1.30
Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. J Virol (2008) 1.30
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother (1998) 1.29
Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase. Proc Natl Acad Sci U S A (1996) 1.28
Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol (1990) 1.20
Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology (2007) 1.19
Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol (1998) 1.15
PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology (2010) 1.15
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol (1990) 1.13
Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J Virol (1999) 1.11
Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J Clin Microbiol (1990) 1.10
Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses (2001) 1.09
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol (2001) 1.09
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One (2010) 1.09
Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol (2003) 1.08
HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies. AIDS Res Hum Retroviruses (2011) 1.07
Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p56lck. Proc Natl Acad Sci U S A (2004) 1.03
Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. J Virol (1998) 1.02
Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys. J Virol (2010) 1.01
Differential effects on human immunodeficiency virus type 1 replication by alpha-defensins with comparable bactericidal activities. J Virol (2004) 0.99
Computational and serologic analysis of novel and known viruses in species human adenovirus D in which serology and genomics do not correlate. PLoS One (2012) 0.93
CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin Exp Immunol (1992) 0.89
Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid. Antimicrob Agents Chemother (2002) 0.89
High throughput quantitative colorimetric microneutralization assay for the confirmation and differentiation of West Nile Virus and St. Louis encephalitis virus. Am J Trop Med Hyg (2010) 0.86
Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J Virol (1990) 0.84
Phosphorothioate and cordycepin analogues of 2',5'-oligoadenylate: inhibition of human immunodeficiency virus type 1 reverse transcriptase and infection in vitro. Proc Natl Acad Sci U S A (1989) 0.83
Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia. J Virol (1998) 0.82
In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes. PLoS One (2012) 0.81
Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies. Vaccine (2013) 0.80
Antifusion activity in sera from persons infected with human immunodeficiency virus type 1. J Clin Microbiol (1990) 0.77
Antihuman Immunodeficiency Virus Type 1 (HIV-1) Activity of Rare Earth Metal Complexes of 4-Hydroxycoumarins in Cell Culture. Bioinorg Chem Appl (2006) 0.75
Synthesis and Inhibiting Activity of Some 4-Hydroxycoumarin Derivatives on HIV-1 Protease. ISRN Pharm (2011) 0.75
An improved microtiter assay for evaluating anti-HIV-1 neutralizing antibodies from sera or plasma. BMC Infect Dis (2003) 0.75
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Molecular cloning of lymphadenopathy-associated virus. Nature (1985) 2.22
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother (1986) 1.51
Anti-viral activity of amphotericin B methyl ester: inhibition of HTLV-III replication in cell culture. Biochem Pharmacol (1986) 1.48
Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic. Virology (1986) 1.18
Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1987) 1.13
Application of an objective biological assay of human interferons to clinical specimens and a survey of a normal population. J Clin Microbiol (1985) 1.11
Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet (1987) 1.09
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol (1999) 5.83
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (1988) 3.32
CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens. Neurology (2001) 2.88
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1988) 1.86
Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr (1989) 1.75
Epidermal growth factor. Physical and chemical properties. J Biol Chem (1972) 1.69
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A (1989) 1.64
Lead ion and phosphatase histochemistry. I. Nonenzymatic hydrolysis of nucleoside phosphates by lead ion. J Histochem Cytochem (1966) 1.59
Synthesis of (3H)DNA complementary to ovalbumin messenger RNA: evidence for limited copies of the ovalbumin gene in chick oviduct. Proc Natl Acad Sci U S A (1973) 1.52
Epidermal growth factor: high and low molecular weight forms. Proc Natl Acad Sci U S A (1970) 1.42
Lead ion and phosphatase histochemistry. II. Effect of adenosine triphosphate hydrolysis by lead ion on the histochemical localization of adenosine triphosphatase activity. J Histochem Cytochem (1966) 1.35
Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology (1990) 1.33
Atomic force microscopy investigation of human immunodeficiency virus (HIV) and HIV-infected lymphocytes. J Virol (2003) 1.32
Topology of the outer segment membranes of retinal rods and cones revealed by a fluorescent probe. Science (1974) 1.31
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother (1998) 1.29
A potential source of electrophoretic artifacts in polyacrylamide gels. Biochim Biophys Acta (1967) 1.28
Light and electron microscopic studies of pigment in human and rhesus monkey substantia nigra and locus coeruleus. Anat Rec (1966) 1.28
GTP hydrolysis in intact rod outer segments and the transmitter cycle in visual excitation. Nature (1979) 1.25
A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochem Biophys Res Commun (1987) 1.20
Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol (1990) 1.20
Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis. AIDS Res Hum Retroviruses (1987) 1.19
Infection of the HTLV-II-bearing T-cell line C3 with HTLV-III/LAV is highly permissive and lytic. Virology (1986) 1.18
Biologic and immunologic characterization and physical separation of ACTH and ACTH fragments in the ectopic ACTH syndrome. J Clin Invest (1973) 1.17
Physical and chemical properties of Moloney murine leukemia virus p30 protein: a major core structural component exhibiting high helicity and self-association. J Mol Biol (1976) 1.17
Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol (1998) 1.15
Characterization of the binding protein for epidermal growth factor. J Biol Chem (1974) 1.15
Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J Virol (1999) 1.14
Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology (1990) 1.14
Purification and properties of clostridiopeptidase B (Clostripain). J Biol Chem (1968) 1.14
Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1987) 1.13
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol (1990) 1.13
Application of an objective biological assay of human interferons to clinical specimens and a survey of a normal population. J Clin Microbiol (1985) 1.11
ACTH and MSH production by a single cloned mouse pituitary tumor cell line. Endocrinology (1973) 1.11
Characterization of the high molecular weight form of epidermal growth factor. J Biol Chem (1974) 1.09
Differences between murine leukemia virus and murine sarcoma virus: effects of virion age and multiplicity of infection on viral RNA. Intervirology (1974) 1.09
Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet (1987) 1.09
Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol (1996) 1.07
Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? Lancet (1988) 1.07
Differences between ectopic MSH and pituitary MSH. J Clin Endocrinol Metab (1971) 1.06
Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infections. AIDS (1990) 1.04
Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. J Pharmacol Exp Ther (1990) 1.03
Physical properties of moloney murine leukemia virus high-molecular-weight RNA: a two subunit structure. J Virol (1975) 1.03
Characteristics and isolation of the phagocytosis-stimulating peptide, tuftsin. Biochim Biophys Acta (1973) 1.02
Proceedings: Physiology and enzymology of frog photoreceptor membranes. Exp Eye Res (1974) 1.01
Studies on the active site of clostripain. The specific inactivation by the chloromethyl ketone derived from -N-tosyl-L-lysine. J Biol Chem (1971) 0.98
Molecular weight of frog rhodopsin. Nat New Biol (1972) 0.98
High-affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse (1992) 0.98
Progress in the monitoring of human interferon in body fluids and the phenotypic expression of human interferon activity. Prog Clin Pathol (1984) 0.97
Chinese hamster lung cells synthesize and confine to the cellular domain a collagen composed solely of B chains. Proc Natl Acad Sci U S A (1980) 0.97
Ionic aspects of excitation in rod outer segments. Ciba Found Symp (1975) 0.96
Genetic coding: oligonucleotide coding for first six amino acid residues of the coat protein of R17 bacteriophage. Science (1969) 0.96
Generation and characterization of a human monoclonal antibody that neutralizes diverse HIV-1 isolates in vitro. AIDS (1992) 0.95
Preliminary characterization of the pituitary melanocyte stimulating hormones of several vertebrate species. Endocrinology (1972) 0.95
Persistent coinfection of T lymphocytes with HTLV-II and HIV and the role of syncytium formation in HIV-induced cytopathic effect. Virology (1987) 0.94
Chromatin of the developing chick oviduct: changes in the acidic proteins. Biochim Biophys Acta (1973) 0.93
Antibody-independent, complement-mediated enhancement of HIV-1 infection by mannosidase I and II inhibitors. Antiviral Res (1989) 0.93
Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother (1998) 0.93
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. J Med Chem (1999) 0.92
Cleavage at arginine residues by clostripain. Methods Enzymol (1977) 0.92
Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. AIDS Res Hum Retroviruses (1995) 0.92
Spontaneous and interferon resistant natural killer cell anergy in AIDS. AIDS Res (1986) 0.91
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Res (2001) 0.91
Natural killer cell infection and inactivation in vitro by the human immunodeficiency virus. Hum Pathol (1988) 0.91
Atomic force microscopy imaging of retroviruses: human immunodeficiency virus and murine leukemia virus. Scanning (2004) 0.89
Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: target CD4 recognition and docking mechanism. Proc Natl Acad Sci U S A (1993) 0.89
The N,O-diacetylmuramidase of Chalaropsis species. II. Physical properties. J Biol Chem (1969) 0.88
Human procollagen I. An anionic tropocollagen precursor from skin fibroblasts in culture. Biophys Chem (1973) 0.87
Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation. Eur J Pharmacol (1996) 0.86
Evidence for anti-antibodies in positively stained immune complexes. Immunology (1971) 0.85
Self-insertion of urethral foreign bodies. Psychiatr Q (1968) 0.84
The suppression of non-specific esterase activity in mouse skin sebaceous gland by "CS" gas. Nature (1972) 0.84
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. AIDS Res Hum Retroviruses (1989) 0.83
The contamination of purified collagenase preparations by clostridiopeptidase B (clostripain): the potential effect of studies utilizing collagenase as a highly specific structural tool. Johns Hopkins Med J (1970) 0.83
Phosphorothioate and cordycepin analogues of 2',5'-oligoadenylate: inhibition of human immunodeficiency virus type 1 reverse transcriptase and infection in vitro. Proc Natl Acad Sci U S A (1989) 0.83
Generation of replication-defective helper-free vectors based on simian immunodeficiency virus. Virology (2001) 0.83
Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens. J Interferon Cytokine Res (2001) 0.82
Effective inactivation of human immunodeficiency virus with chlorhexidine antiseptics containing detergents and alcohol. J Hosp Infect (1990) 0.81
Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1. Antiviral Res (2000) 0.81
Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. J Med Primatol (1990) 0.81
Inhibition of cis-diamminedichloroplatinum (II)--induced renal toxicity in the rat. Cancer Chemother Pharmacol (1986) 0.81
Drug leads from the Kallawaya herbalists of Bolivia. 1. Background, rationale, protocol and anti-HIV activity. J Ethnopharmacol (1996) 0.81
Unprecedented forms of vanadium observed within the blood cells of Phallusia nigra using K-edge X-ray absorption spectroscopy. J Inorg Biochem (2001) 0.81
Enzyme histochemical studies on rat lungs. I. An improved technique for the demonstration of enzyme activity in alveolar tissue. Histochem J (1969) 0.81
Chinese hamster lung cell polysomes direct the synthesis of a single molecular weight species of procollagen alpha chains. J Biol Chem (1978) 0.81
Pica in adults. Calif Med (1968) 0.81